Photobiomodulation therapy (PBMT) is marketed like universal biology: shine the right wavelength, hit cytochrome c oxidase, boost ATP, accelerate healing. But this Deep Dive unpacks a hidden variable that can make “standard dosing” either ineffective or unsafe: melanin. Using a 2026 narrative review from researchers at the University of São Paulo, we trace the physics of a photon entering the body, how melanin’s absorption overlaps the therapeutic “optical window,” and why simply “turning up the laser” can backfire — creating heat and reactive species in the epidermis while deeper target tissues get little benefit. We also confront a data problem: trials may include darker phototypes, but too often outcomes aren’t analyzed by skin type, creating a misleading “average” that masks risk. Finally, we outline practical fixes — wavelength selection, spot size adjustments, and pigmentation-sensitive, feedback-guided dosimetry — so PBMT can become truly personalized and equitable.

(Educational content only, not medical advice.)

Article Discussed in Episode:

Key Quotes From Dr. Mike:

Regarding melanin: “It literally absorbs the photons before they can ever reach the deeper tissues.”

“For individuals with darker skin tones, this can result in totally subtherapeutic treatments.”

“They currently do not differentiate dosing parameters based on skin pigmentation.”

“The physics of a photon is constant. But the biological filter it’s passing through is wildly diverse.”

“At 660 nm… 21 mm in lighter skin… but in darker skin it drops to 14 mm.”

“We need to stop treating light therapy like a one-size-fits-all t-shirt… and treat it like a custom tailored suit.”

Key Points

PBMT’s core mechanism: photons → mitochondrial chromophores (cytochrome c oxidase) → ATP support and healing.
The optical window (≈600–1100 nm) overlaps with melanin’s strong absorption (≈600–900 nm).
Darker skin = more melanin absorption, meaning less light reaches deeper tissue → risk of subtherapeutic dosing.
“Just increase power” can be dangerous: melanin absorbs more energy → heat + ROS/RNS → redness, pain, burns.
Guideline gap: WALT dosing recommendations don’t meaningfully adjust for pigmentation.
Data aggregation problem: studies include darker phototypes but often don’t stratify outcomes, producing “average” conclusions that can hide harm.
Fixes the paper argues for: longer wavelengths (e.g., 830–1064 nm), larger spot sizes, gradual ramping + patient sensory monitoring, and pigmentation-sensitive dosimetry models.
Bottom line: melanin isn’t a deal-breaker — it’s a dosing variable that must be accounted for.

Episode timeline

0:19–0:58 — Cold open: expensive PBM devices can still burn patients if not calibrated to skin tone
0:58–1:49 — The core question: Is PBMT free from racial bias? Grounding source + paper title
1:49–2:47 — PBMT basics: cytochrome c oxidase, ATP synthesis, “good biology”
2:47–4:29 — The physics: optical window (600–1100 nm) meets endogenous chromophores; melanin’s peak absorption overlaps therapy
4:29–5:27 — Why darker skin can get subtherapeutic dosing: photons absorbed before reaching target tissue
5:27–7:56 — Why “turn it up” is risky: melanin heat + ROS/RNS → pain, redness, superficial thermal injury (cake/oven analogy)
7:56–10:50 — Guideline + research bias: WALT doesn’t differentiate by pigmentation; studies include darker phototypes but don’t analyze by skin type (“mathematical erasure”)
10:50–12:33 — Solution #1: wavelength selection; penetration example (660 nm vs 830 nm) shows gap narrowing for darker skin
12:33–13:39 — Solution #2–3: larger spot size + gradual increments with sensory monitoring (patient feedback as safety gauge)
13:39–15:27 — Big takeaway: pigmentation-sensitive dosimetry is a necessity; closing question + outro

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

Stay up-to-date on social media:

Dr. Mike Belkowski:

BioLight: